Insmed (INSM) Share-based Compensation (2010 - 2026)
Insmed (INSM) posted quarterly Share-based Compensation of $45.8 million for Q1 2026, up 16.54% year-over-year from $39.3 million in Q1 2025, and up 17.2% quarter-over-quarter from $39.0 million in Q4 2025.
Insmed (INSM) Share-based Compensation (2010 - 2026) Analysis & Trends
Insmed's Share-based Compensation history runs 17 years deep, the most recent figure standing at $45.8 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 16.54% year-over-year to $45.8 million; the TTM figure through Mar 2026 stood at $159.2 million (up 38.86% YoY), while the FY2025 annual figure was $152.7 million, up 57.7% from the prior year.
- Share-based Compensation for Q1 2026 stood at $45.8 million, up from $39.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $45.8 million in Q1 2026, with the low at $12.8 million in Q1 2022.
- The 5-year median for Share-based Compensation is $21.4 million (2024), against an average of $25.2 million.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation surged 84.56% in 2025, then gained 16.54% in 2026.
- Insmed's Share-based Compensation stood at $15.0 million in 2022, then jumped by 33.67% to $20.0 million in 2023, then surged by 32.88% to $26.6 million in 2024, then jumped by 47.02% to $39.0 million in 2025, then rose by 17.2% to $45.8 million in 2026.
- Business Quant data shows INSM's Share-based Compensation at $45.8 million in Q1 2026, $39.0 million in Q4 2025, and $31.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.25 Mn |
| Jun 30, 2026 | 41.25 Mn |
| Mar 31, 2026 | 45.75 Mn |
| Mar 31, 2026 | 45.75 Mn |
| Dec 31, 2025 | 39.04 Mn |
| Dec 31, 2025 | 39.04 Mn |
| Sep 30, 2025 | 31.43 Mn |
| Sep 30, 2025 | 31.43 Mn |
| Jun 30, 2025 | 42.98 Mn |
| Jun 30, 2025 | 42.98 Mn |
| Mar 31, 2025 | 39.26 Mn |
| Mar 31, 2025 | 39.26 Mn |
| Dec 31, 2024 | 26.55 Mn |
| Dec 31, 2024 | 26.55 Mn |
| Sep 30, 2024 | 25.55 Mn |
| Sep 30, 2024 | 25.55 Mn |
| Jun 30, 2024 | 23.29 Mn |
| Jun 30, 2024 | 23.29 Mn |
| Mar 31, 2024 | 21.45 Mn |
| Mar 31, 2024 | 21.45 Mn |